Bristol seeks another celmod use
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Golcadomide will begin a new pivotal trial in follicular lymphoma.
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
The EU recommendation for odronextamab comes after a US rejection in March.
Merck and Daiichi’s first ADC attempt is knocked back, while Geron gets its inaugural approval.
The decision highlights the fact that Regeneron is still doing dose-finding work for odronextamab.